Apollon Wealth Management LLC Has $538,000 Stake in Edwards Lifesciences Co. (NYSE:EW)

Apollon Wealth Management LLC cut its position in Edwards Lifesciences Co. (NYSE:EW) by 14.0% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 7,271 shares of the medical research company’s stock after selling 1,187 shares during the quarter. Apollon Wealth Management LLC’s holdings in Edwards Lifesciences were worth $538,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in EW. Alpha Financial Partners LLC acquired a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at $693,000. Koshinski Asset Management Inc. acquired a new stake in Edwards Lifesciences in the third quarter valued at about $396,000. Vontobel Holding Ltd. boosted its stake in Edwards Lifesciences by 5.7% in the third quarter. Vontobel Holding Ltd. now owns 439,106 shares of the medical research company’s stock valued at $28,977,000 after buying an additional 23,560 shares in the last quarter. nVerses Capital LLC bought a new position in Edwards Lifesciences in the third quarter valued at about $792,000. Finally, Trust Co. of Vermont raised its stake in Edwards Lifesciences by 36.1% during the third quarter. Trust Co. of Vermont now owns 3,019 shares of the medical research company’s stock worth $199,000 after acquiring an additional 801 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Insider Activity

In related news, VP Daniel J. Lippis sold 2,500 shares of the firm’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $74.08, for a total transaction of $185,200.00. Following the transaction, the vice president now directly owns 23,189 shares of the company’s stock, valued at $1,717,841.12. This trade represents a 9.73 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Performance

EW opened at $75.83 on Thursday. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The company has a market cap of $44.72 billion, a price-to-earnings ratio of 10.94, a PEG ratio of 3.64 and a beta of 1.10. The company’s fifty day moving average price is $72.47 and its two-hundred day moving average price is $69.32. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. On average, analysts expect that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

EW has been the topic of a number of research analyst reports. Wolfe Research lowered shares of Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 target price on the stock. in a research report on Thursday, January 16th. The Goldman Sachs Group raised their price objective on Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, December 5th. Morgan Stanley upped their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a report on Wednesday. Stifel Nicolaus upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and increased their target price for the company from $75.00 to $90.00 in a research report on Thursday, January 30th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $85.00 price target on shares of Edwards Lifesciences in a report on Wednesday. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $79.71.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.